It has been proposed that Hsp90β‐selective inhibitors could serve as a drug target for treating patients with metabolic disorders such as obesity‐induced fatty liver disease, type 2 diabetes, and atherosclerosis. The gene discussed is HSP90AB1; the disease is atherosclerosis.